Publications

May, 2025

Comparative analysis of circulating tumour cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy

University Medical Center Hamburg-Eppendorf

May, 2025

Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumour Cells

Cleveland Clinic / University of Arizona / USC / University Hospital Zürich

May, 2025

A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells

Veneto Institute of Oncology, Italy

May, 2025

Comparison of CellSearch versus Parsortix circulating tumour cell enumeration and molecular characterisation: A pilot study in metastatic prostate cancer patients

Western University, London (Ontario, Canada)

April, 2025

Red blood cell–tumour cell interactions promote tumour cell progression

University Medical Center Hamburg-Eppendorf

April, 2025

A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas

Trinity College Dublin, Ireland

January, 2025

A melanoma brain metastasis CTC signature and CTC:B cell clusters associate with secondary liver metastasis: a melanoma brain-liver metastasis axis

The University of New Mexico Comprehensive Cancer Center, United States

January, 2025

Digoxin for reduction of circulating tumour cell cluster size in metastatic breast cancer

Institute of Molecular Health Sciences, ETH Zurich, Switzerland

January, 2025

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma

University Medical Center Hamburg-Eppendorf

December 2024

CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma – a short report

School of Medicine and Population Health, University of Sheffield, UK

October, 2024

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Analysis of Circulating Tumor Cells Lab, Department of Chemistry, National and Kapodistrian University of Athens, Greece

October 2024

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer

Comprehensive Cancer Center, Medical University of Vienna, Austria

September, 2024

Low‑pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple‑negative breast cancer

Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Italy

September, 2024

KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

University Hospital Hamburg-Eppendorf, Germany

August, 2024

Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

ANGLE Europe Limited, Guildford, UK, University of Rochester, Rochester, US, and MD Anderson Cancer Center, Houston, US

August 2024

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland

July 2024

Combined microfluidic enrichment and staining workflow for single-cell analysis of circulating tumor cells in metastatic prostate cancer patients

Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

June, 2024

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

March, 2024

Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium

Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

January 2024

Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

January 2024

Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix System

ANGLE Europe Limited, Guildford, UK published by journal of Current Issues in Molecular Biology

December 2023

Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy

Trinity College Dublin, Ireland published by the journal Frontiers in Cell and Developmental Biology

November, 2023

Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not Metastasis

Department of Internal Medicine, University of New Mexico Health Sciences Center, United States

November, 2023

DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts

Department of Obstetrics and Gynaecology, Heinrich Heine University of Duesseldorf, Germany

October, 2023

Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping

Institute of Cancer and Genomic Sciences, University of Birmingham, UK, published by the British Journal of Cancer

September, 2023

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients

Research Institute for Women’s Health, University of Tubingen, Tubingen, Germany published by International Journal of Molecular Sciences

August, 2023

Analytical performance of the FDA-cleared Parsortix^®PC1 system

ANGLE Europe Limited, Guildford, UK published by Journal of Circulating Biomarkers

August, 2023

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

National and Kapodistrian University of Athens, Athens, Greece published by Cancer Research Communications

June, 2023

Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status

Fondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy, published by International Journal of Molecular Sciences

June, 2023

Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C‑ProMeta‑1)

Dept. of Urology, University College London Hospitals, London, UK, published by BMC Cancer

June, 2023

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer

Department Medical Oncology, Institute of Oncology, Ljubljana, Slovenia, published by Cancers

May, 2023

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer

Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, published by International Journal of Molecular Sciences

March, 2023

Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients

German Center for Lung Research, Grosshansdorf, Germany, published by Molecular Oncology, March 2023

March, 2023

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer

National and Kapodistrian University of Athens, Athens, Greece published by Cancers

March, 2023

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients

University Medical Center Hamburg-Eppendorf, Hamburg, Germany, published by Cancer Cell International

January, 2023

The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, published by Frontiers in Oncology

November, 2022

Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma

University Hospital Hamburg-Eppendorf, Hamburg, Germany, published by Biomedicines

November, 2022

Effect of short-term storage of blood samples on gene expression in lung cancer patients

Medical University of Vienna, Vienna, Austria, published by Clinical Chemistry and Laboratory Medicine

November, 2022

The RPL/RPS Gene Signature of Melanoma updates CTCs Associates with Brain Metastasis

University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA, published by Cancer Research Communications

October, 2022

A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix^®PC1 System

University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA , published by Cancers

October, 2022

Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer

Universidade de Vigo, Vigo, Spain and the Galicia Sur Health Research Institute , Spain, published by Genomics,

September, 2022

Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients

University Hospital Hamburg-Eppendorf, Hamburg, Germany, published by Cancers

September, 2022

Comparison of microfuidic platforms for the enrichment of circulating tumor cells in breast cancer patients

Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, published by Breast Cancer Research and Treatment

September, 2022

Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester, Rochester, New York and ANGLE Europe Limited, Surrey Research Park, Guildford, Surrey, United Kingdom, published by Obstetrics & Gynecology

July, 2022

Characterizing the epithelial–mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma

Institute of Head and Neck Studies and Education, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, published by Head and Neck

July, 2022

Powering single‑cell genomics to unravel circulating tumour cell subpopulations in non‑small cell lung cancer patients

Edith Cowan University, Perth, Australia, published by Journal of Cancer Research and Clinical Oncology

June, 2022

Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions

University Hospital and Medical Faculty, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, published by Cytometry

June, 2022

National and Kapodistrian University of Athens, Greece, published by Cancers

June, 2022

The metastatic spread of breast cancer accelerates during sleep

Molecular Oncology Laboratory at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, published by Nature

May, 2022

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

National and Kapodistrian University of Athens, Greece, published by Clinical Epigenetics

May, 2022

Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer

School of Medical and Health Sciences, Edith Cowan University, Perth, Australia, published by Translational Lung Cancer Research

April, 2022

Invadopodia play a role in prostate cancer progression

School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK, published by BMC Cancer

March, 2022

Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, published by Clinical Chemistry

February, 2022

An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression

Molecular Oncology Laboratory, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, published by Cancer Research

February, 2022

Microtubule disruption reduces metastasis more effectively than primary tumor growth

University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, published by Breast Cancer Research

January, 2022

Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid Biopsy

Universidad Autonoma de Madrid, Madrid, Spain, published by Frontiers in Pharmacology

January, 2022

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early‑stage triple negative breast cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, published by Scientific Reports

January, 2022

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer

University of Southern California Norris Cancer Center, Los Angeles, United States, published by Annals of Surgical Oncology

December, 2021

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients

Edith Cowan University, Perth, Australia, published by Cancers

November, 2021

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment

National and Kapodistrian University of Athens, Greece, published by Cancers

November, 2021

Cancer Stem Cell-like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer

Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Austria, published by Journal of Personalized Medicine

November, 2021

Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery

Institute of Head and Neck Studies and Education, Institute of Cancer and Genomic Sciences, University of Birmingham, UK, published by Cancers

August, 2021

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small cell lung cancer treated with pembrolizumab

Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain published by Molecular Oncology

August, 2021

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer

Department of Urology, Medical University Innsbruck, Innsbruck, Austria published by Biomedicines

July, 2021

Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms

UCL Cancer Institute, University College London, London, UK, published by Endocrine-Related Cancer

July, 2021

Morphological features of breast cancer circulating tumor cells in blood after physical and biological type of isolation

Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia published by Radiology and Oncology

June, 2021

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis

University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by International Journal of Molecular Sciences

May, 2021

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR

National and Kapodistrian University of Athens, Greece published by Cancers

May, 2021

A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patients

Washington University School of Medicine, St. Louis, Missouri, United States published by PLoS ONE

May, 2021

Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma

Department of Gastro-Intestinal Surgery, University Hospital Ghent, Belgium published by PLoS ONE

April, 2021

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer

National and Kapodistrian University of Athens, Athens, Greece published by Frontiers in Cell and Developmental Biology

March, 2021

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy published by ESMO Open / Cancer Horizons

February, 2021

Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells

University Medical Centre Hamburg-Eppendorf, Hamburg, Germany published by Cancers

January, 2021

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD‑L1during osimertinib treatment in NSCLC patients

National and Kapodistrian University of Athens, Greece published by Nature Scientific Reports

January, 2021

Proficiency testing to assess technical performance for CTC-processing and detection methods in CANCER-ID

The CANCER-ID Consortium published by Clinical Chemistry

January, 2021

EMT‑independent detection of circulating tumor cells in human blood samples and pre‑clinical mouse models of metastasis

London Regional Cancer Program and Flow Cytometry, London Health Sciences Centre; Departments of Anatomy & Cell Biology and Oncology, Western University; and Lawson Health Research Institute, London, Ontario, Canada published by Clinical & Experimental Metastasis,

October, 2020

Antigen-agnostic microfluidics based circulating tumor cell enrichment and downstream molecular characterization

Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, United States published by PLOS ONE

September, 2020

Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells

Department of Bioscience, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Switzerland published by Cell Reports

July, 2020

A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, United States published by International Journal of Molecular Sciences

June, 2020

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy

Laboratory of Translational Oncology, School of Medicine, University of Crete, Greece published by Cancers

April, 2020

Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma

University of Athens, Greece published by Nature Scientific Reports

February, 2020

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

Liquid Biopsy Analysis Unit, Health Research Institute of Santiago, Spain published by Cells

February, 2020

Cancer transcriptomic profiling from rapidly enriched circulating tumor cells

Keck School of Medicine, University of Southern California, United States published by International Journal of Cancer

February, 2020

ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium

University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Journal of Neuro-Oncology

February, 2020

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression

Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy published by International Journal of Molecular Sciences

February, 2020

Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients

University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers

February, 2020

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells

Edith Cowan University, Perth, Australia published by British Journal of Cancer

October, 2019

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients

University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers

September, 2019

Non-invasive detection of clinically significant prostate cancer using circulating tumor cells

Barts Cancer Institute, Queen Mary University of London, UK published by Journal of Urology

August, 2019

Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects

Institute of Head and Neck Studies and Institute of Immunology and Immunotherapy, University of Birmingham, UK published by Cancers

August, 2019

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer

Medical University of Vienna, Austria published by Cells

June, 2019

Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance

University Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, Germany published by Cancers

June, 2019

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Department of Oncology, Hematology and Bone Marrow Transplantation with section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers

April, 2019

PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling

Biomarker Research Program, Houston Methodist Research Institute in conjunction with the Center for Precision Health, University of Texas and MD Anderson Cancer Center, Houston, United States published by International Journal of Molecular Sciences

March, 2019

Assessing metastatic potential of breast cancer cells based on EGFR dynamics

The University of Texas MD Anderson Cancer Center, Houston, United States published by Nature

February, 2019

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products

Disseminated Cancer Cell Network (DCCNet) at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany published by Clinical Chemistry

February, 2019

Neutrophils escort circulating tumour cells to enable cell cycle progression

Cancer Metastasis Laboratory, University of Basel and collaborators published by Nature

January, 2019

Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples

Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany published by International Journal of Cancer

January, 2019

Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding

Cancer Metastasis Laboratory, University of Basel and collaborators published by Cell

November, 2018

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

Cancer Metastasis Laboratory, University of Basel, Switzerland published by Breast Cancer Research

August, 2018

Detection of circulating tumour cell clusters in human glioblastoma

Cancer Metastasis Laboratory, University of Basel and collaborators published by British Journal of Cancer

July, 2018

The Parsortix^®Cell Separation System – A Versatile Liquid Biopsy Platform

ANGLE plc published by Cytometry Part A, Journal of Quantitative Cell Science

March, 2018

The precious cell block

Department of Cellular Pathology, Musgrove Park Hospital, Taunton UK published by the Journal of Clinical Pathology

January, 2018

Challenges in using liquid biopsies for gene expression profiling

University of Southern California Norris Comprehensive Cancer Center published by Oncotarget

January, 2018

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells

University Medical Centre Hamburg-Eppendorf, Medical University of Graz and Stockholm University published by Clinical Chemistry

November, 2017

Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells

Medical University of Vienna published by Oncotarget

September, 2017

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells

Clinic for Urology, University Hospital Muenster, Muenster, Germany published by Oncotarget

August, 2017

A novel workflow to enrich and isolate patient-matched EpCAM high and EpCAM low/negative CTCs enables the comparative characterization of the PIK3CA status in metastatic breast cancer

Heinrich Heine University of Dusseldorf published by International Journal of Molecular Sciences

June, 2017

The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis

Barts Cancer Institute published by Clinical Cancer Research

September, 2016

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells

University Medical Centre Hamburg-Eppendorf (UKE) published by Clinical Chemistry

January, 2016

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells

University Medical Centre Hamburg-Eppendorf (UKE) published by International Journal of Cancer

November, 2015

Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumor cells in patients with small cell lung cancer

Cancer Research UK Manchester Institute and Christie NHS Foundation Trust, Manchester UK published by Royal Society of Chemistry Analyst publication

September, 2015

Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System

Barts Cancer Institute, published by PLOS ONE

June 2025

Comparative Molecular Analysis of CTCs and ctDNA Detection using ANGLE’s Parsortix® System

ANGLE Europe Ltd, Guildford, UK, published at EACR Annual Meeting 2025

June 2025

Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples.

ANGLE Europe Limited, Guildford, UK, published at EACR Annual Meeting 2025

April, 2025

Analytical validation of ANGLE’s combined IF and FISH assay for assessment of HER2 in circulating tumor cells

ANGLE Europe Limited, Guildford, UK, published at AACR Annual Meeting 2025

January 2025

DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients

ANGLE Europe Limited, Guildford, UK, published at the 8th Annual DDR Inhibitors Summit 2025

December 2024

SABCS: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?

November 2024

AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments

ANGLE Europe Limited, Guildford, UK, Published at the AACR LBx Conference 2024

November 2024

AACR LBx 24 – Investigating PD-L1 status in Circulating Tumour Cells isolated from the blood samples of lung cancer patients

November 2024

EACR LBx 24 – Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based Methodology

ANGLE Europe Limited, Guildford, UK, Published at the EACR LBx Conference 2024

November 2024

EACR LBx 24 – Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples.

ANGLE Europe Limited, Guildford, UK, Published at the EACR LBx Conference 2024

September 2024

DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays

In this proof of concept study, we aimed to assess the performance of ANGLE's IF assays for the identification of epithelial, mesenchymal and transitioning CTCs, and to determine DDR status on the identified CTCs, by combining the use of IF with Parsortix technology.

June 2024

Targeted Sequencing of Circulating Tumour Cells Captured by Parsortix System Enables Low Frequency Variant Analysis with VarMap^TM Pan-Cancer NGS Panel

ANGLE Europe Limited, Guildford, UK, published at the EACR Annual Meeting 2024

June 2024

Detection of DNA damage in circulating tumour cells harvested from blood samples of ovarian and prostate cancer patients

ANGLE Europe Limited, Guildford, UK, published at the EACR Annual Meeting 2024

April 2024

Development and analytical validation of a novel assay for HER2 assessment on circulating tumour cells using Parsortix® isolation and BioView imaging technologies

ANGLE Europe Limited, Guildford, UK, published at the AACR Annual Meeting 2024

May 2024

CellKeep^TM slide enhances retention of circulating tumour cells harvested from patient blood samples using the Parsortix^® system

ANGLE Europe Limited, Guildford, UK, published at the New Frontiers in Liquid Biopsies: Data, Technology and Translational Potential Meeting 2024

March 2024

Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumour Cell Analysis

ANGLE Europe Limited, Guildford, UK, published at the 14th European Breast Cancer Conference March 22 2024

March 2024

Interrogating HER2 status in Circulating Tumor Cells isolated using the Parsortix® System from Metastatic Breast Cancer patients

ANGLE Europe Limited, Guildford, UK, published at the 14th European Breast Cancer Conference March 22 2024

May, 2023

Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate Cancer – NCRI Cancer Conference abstracts

May, 2023

Detection and molecular characterization of EpCAM positive and EpCAM negative circulating tumor cells isolated from SCLC (small cell lung cancer) patients using an epitope independent platform

Cancer Research UK Manchester Institute, as presented at the 10th ISMRC International Symposium on Minimal Residual

May, 2023

Integration of RNA and DNA blood-borne cancer biomarkers

Cancer Research UK Manchester Institute, as presented at the 10th ISMRC International Symposium on Minimal Residual

April, 2023

Evaluation of HER2 status in circulating tumour cells isolated using ANGLE’s Parsortix^®System

ANGLE Europe Limited as presented at the American Association for Cancer Research, Florida, USA

March, 2023

Detection of DNA Damage in Circulating Tumor Cells Isolated using the Parsortix^®System

ANGLE plc as presented at the European Association for Cancer Research, Florence, Italy

December, 2022

Identification of circulating tumor cells captured by the FDA cleared Parsortix^®PC1 System from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

ANGLE Europe Limited as presented at the San Antonio Breast Cancer Symposium, Texas, USA

December, 2022

A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix^®PC1 System in support of FDA clearance

MD Anderson Cancer Center as presented at the San Antonio Breast Cancer Symposium, Texas, USA

October, 2022

Maximizing clinical utility of liquid biopsy utilizing a single blood sample for ctDNA and CTC analysis using the Parsortix^®System

ANGLE Europe Limited as presented at the 4th Annual International Society of Liquid Biopsy Congress in Miami, Florida, USA

September, 2022

Morphological Characteristics of Malignancy in Circulating Tumor Cells

ANGLE Onc-ADaPT Labs as presented at the 100th American Society of Clinical Pathology (ASCP) Meeting in Chicago, Illinois, USA

May, 2022

Antigen-independent enrichment of circulating tumour cells in metastatic breast and ovarian cancer

Trinity College Dublin as presented at EACR Liquid Biopsies Conference

April, 2022

Epithelial and Mesenchymal CTC Detection in Triple Negative Breast Cancer Patients using ANGLE’s Parsortix^®System

ANGLE plc, as presented at AACR

8-12 November, 2021

Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate Cancer

Barts Cancer Institute, Queen Mary University of London, UK as presented at NCRI Festival

September, 2021

Detection of circulating tumor cells in platinum-resistant ovarian cancer patients enrolled in the GANNET53 study

Medical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece

September, 2021

Molecular characterization of circulating tumor cells enriched by a microfluidic platform in patients with non-small cell lung cancer

Medical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece

September, 2021

Detection of p53 aggregates in circulating tumour cells of patients with small cell lung cancer

Medical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece

April - May, 2021

Mesenchymal markers: the new avenue for circulating tumor cells detection

ANGLE plc as presented at AACR 2021 Virtual Meeting

April - May, 2021

Investigation of PD-L1 expression in circulating tumor cells isolated using the Parsortix^®system in metastatic lung and breast cancer patients

ANGLE plc as presented at AACR 2021 Virtual Meeting

March, 2020

Isolation of ovarian cancer circulating tumor cells using an epitope independent microfluidic cell capture device and their interrogation using a multiplex gene expression assay or immunofluorescence

ANGLE plc and University of Rochester Medical Center, Wilmot Cancer Institute as presented at SGO

March - April, 2019

Molecular characterisation of circulating tumor cells in head and neck squamous cell carcinoma: Direct comparison of a label-independent size-based microfluidic device with EpCAM-based CTC enrichment

University of Athens, Greece as presented at AACR 2019 in Atlanta, United States

March - April, 2019

Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management?

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy as presented at AACR 2019 in Atlanta, United States

March - April, 2019

Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC)

Northwestern University, Chicago, United States as presented at AACR 2019 in Atlanta, United States,

March - April, 2019

Detection of CK-19 mRNA positive CTCs, isolated with a size-based microfluidics platform, in NSCLC patients under osimertinib therapy

University of Athens, Greece as presented at AACR 2019 in Atlanta, United States

March - April, 2019

Parsortix^®system: Analytic performance evaluation using ovarian cancer cell lines

ANGLE plc as presented at AACR 2019 in Atlanta, United States

March - April, 2019

Multiplex gene expression using the HyCEAD assay in CTCs isolated with the Parsortix^®system

ANGLE plc as presented at AACR 2019 in Atlanta, United States,

October, 2018

A novel method to enrich and characterize circulating fetal cells using the Parsortix^®cell separation system

ANGLE plc as presented at the 6th Annual Advances in Prenatal Molecular Diagnostics conference in Cambridge

May, 2018 (ISMRC 2018)

CTCs in Prostate Cancer: Molecular Characterization, Immunostaining and Enumeration by Combination of Label-free Parsortix^®CTC Enrichment and AdnaTest Prostate Cancer Panel Expression Profiling for PSMA, AR and AR-V7

ANGLE plc and QIAGEN GmbH as presented at the 11th International Symposium on Minimal Residual Cancer in Montpellier, France,

April, 2018

A novel ex vivo culture workflow to enrich and expand circulating tumor cells (CTCs) from patients with Stage III/IV Breast Cancer

Robert H Lurie Comprehensive Cancer Center and the Feinberg School of Medicine, Northwestern University, Chicago as presented at AACR 2018 in Chicago

April, 2018

A fast and sensitive workflow to screen therapy-relevant mutations in circulating tumor cells and quantification of cancer-associated exosomal mRNA in plasma of cancer patients

Bayer AG, Pharmaceutical Division as presented at AACR 2018 in Chicago

March, 2018

Ember Trial: Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting with a Pelvic Mass

ANGLE plc and University of Rochester Medical Center, Wilmot Cancer Institute as presented at SGO

December, 2017

The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer

University of Southern California Norris Comprehensive Cancer Center as presented at the San Antonio Breast Cancer Symposium in Texas

November, 2017

Highly Multiplexed Molecular Analysis of Circulating Tumor Cells Enriched Using the Epitope Independent Parsortix^®System

ANGLE plc as presented at the AACC Emerging Clinical & Laboratory Diagnostics in the Healthcare Ecosystem (ECLD) conference in San Diego

October, 2017

Establishment and evaluation of a novel method for the size separation of disseminated tumor cells from cancer patient bone marrow by a microfluidic platform

Universityclinic Tuebingen, Germany as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes

October, 2017

Parsortix^®system enables isolation of viable CTCs from leukapheresis product with subsequent culture

Heinrich-Heine University Duesseldorf, Germany as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes

October, 2017

The novel association of circulating tumour cells and circulating megakaryocytes with prostate cancer prognosis

Barts Cancer Institute, Queen Mary University of London as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes

October, 2017

Single CTC isolation for genetic analysis using Parsortix^®and VyCAP

VyCAP B.V. as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes

August, 2016 (AACC 2016)

Antibody-free microfluidics-based circulating tumor cell enrichment by Parsortix^®and downstream molecular characterization by Quantigene branched DNA technology

MD Anderson as presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia

July, 2016 (EACR 2016)

Surface marker independent enrichment of circulating or disseminated cancer cells from blood or lymph nodes using a micro-fluidic device

Fraunhofer ITEM as presented at the 24th Biennial Congress of the European Association for Cancer Research

July, 2016 (EACR 2016)

A highly sensitive method for circulating tumor cell antigen quantification in liquid biopsy

ANGLE Research & Development Laboratory as presented at the 24th Biennial Congress of the European Association for Cancer Research

April, 2016

Combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer

Cancer Research UK Manchester Institute as presented at the American Association for Cancer Research Annual Meeting

March, 2016

The combination of Parsortix^®system and CellCelector™ micromanipulator enables the characterization of EpCAM negative circulating tumor cells in breast cancer

Heinrich-Heine University, Düsseldorf, Germany as presented at the 10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment

September, 2015

Circulating rare cells enable highly efficient cancer detection

Medical University of Vienna, as presented at 18th ECCO – 40th ESMO European Cancer Congress

11 June, 2015

Intra-tumor heterogeneity in prostate cancer and the implication in CTC analysis

Barts Cancer Institute, as presented at a symposium hosted by the British Association for Cancer Research and Cancer Research UK on

April, 2015

Circulating rare cells enable highly efficient cancer detection

Medical University of Vienna, as presented at the AACR conference

April, 2015

Enrichment and isolation of uncontaminated breast cancer cells from human blood samples

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, as presented at the AACR conference